cefotaxime sodium: clinical use

Prescribing considerations

• Obtain appropriate microbiology samples and reassess therapy when susceptibility results become available.
• Consider local resistance patterns and limited activity against some organisms, including many anaerobes, enterococci, MRSA and Pseudomonas aeruginosa.
• Review renal function, beta-lactam allergy history, sodium restriction and concurrent nephrotoxic medicines.
• Avoid unnecessarily rapid intravenous administration, particularly through a central venous catheter.

Contraindications and cautions

• Hypersensitivity to cefotaxime or another cephalosporin.
• Previous immediate or severe hypersensitivity reaction to a penicillin or another beta-lactam antibiotic.

Monitoring

• Renal function, especially with impairment, older age or concurrent nephrotoxic treatment.
• Full blood count during prolonged treatment or if unexplained infection, bleeding or anaemia develops.
• Clinical response, culture results, superinfection and antibiotic-associated colitis.
• Neurological status where accumulation or renal impairment is a concern.
• Liver tests where clinically indicated; cefotaxime can also affect Coombs testing and some non-specific urine glucose tests.

Clinical pharmacology

A parenteral, bactericidal third-generation cephalosporin that inhibits cell-wall synthesis through penicillin-binding proteins. It is substantially eliminated through the kidneys and forms an active metabolite; renal impairment can prolong exposure.

Formulation and product differences

• White or slightly yellow powder requiring reconstitution for intravenous injection or infusion.
• No excipients are listed, although cefotaxime sodium contributes a clinically relevant sodium load.
• Use only clear, particle-free prepared solution; colourless-to-yellow variation can occur.
• Aminoglycosides must not be mixed with cefotaxime in the same parenteral mixture.
• Prepared solution should preferably be used immediately, following local aseptic preparation and storage procedures.

Injection

Route: Parenteral

Strengths: 500 mg, 1 g, 2 g